8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                       ----------------------------------


                                    FORM 8-K

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


        Date of Report (Date of earliest event reported): August 31, 2004



                             TLC VISION CORPORATION
             (Exact name of registrant as specified in its charter)



  NEW BRUNSWICK                     0-29302                    980151150
 (State or other               (Commission File             (I.R.S. Employer
 jurisdiction of                    Number)              Identification Number)
  organization)



          5280 SOLAR DRIVE, SUITE 100                          L4W 5M8
             MISSISSAUGA, ONTARIO                             (Zip Code)
   (Address of principal executive offices)


       Registrant's telephone number, including area code: (905) 602-2020

================================================================================



ITEM 8.01         OTHER EVENTS

                  On August 31, 2004, the Company and OccuLogix, Inc. announced
OccuLogix' filing of its preliminary prospectus in Canada in connection with the
initial public offering of its common stock. A copy of that press release is
attached hereto as Exhibit 99.1.

ITEM 9.01         LIST OF EXHIBITS FILED

                  (c)      Exhibits

                           99.1    OccuLogix' Preliminary Prospectus Press
                                   Release, dated August 31, 2004

                                      * * *




                                       2



                                   SIGNATURES

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

Dated:  August 31, 2004

                                         TLC VISION CORPORATION



                                         By:  /s/ Robert W. May
                                            ---------------------------------
                                             Robert W. May
                                             General Counsel and Secretary




                                       3





                                  EXHIBIT INDEX

Exhibit No.       Description

   99.1           OccuLogix Preliminary Prospectus Press Release, dated
                  August 31, 2004



                                       4

EX-99.1

                                                                    EXHIBIT 99.1



OCCULOGIX, INC. FILES PRELIMINARY PROSPECTUS IN CANADA IN CONNECTION WITH THE
INITIAL PUBLIC OFFERING OF ITS COMMON STOCK


MISSISSAUGA, ONTARIO--(CCNMatthews - Aug. 31, 2004) - OccuLogix, Inc. (formerly
Vascular Sciences Corporation) and its significant stockholder TLC Vision
Corporation announced today that OccuLogix, Inc. has filed a preliminary
prospectus with the Canadian securities regulatory authorities in each of the
provinces of Canada for the initial public offering of its common stock in
Canada. OccuLogix filed a registration statement with the U.S. Securities and
Exchange Commission for the initial public offering of its common stock in the
United States on August 13, 2004. In Canada, the offering is being underwritten
by Citigroup Global Markets Canada Inc., Clarus Securities Inc., Orion
Securities Inc. and Octagon Capital Corporation.

In Canada and the United States, the common stock will only be offered by means
of a prospectus. In the United States, the registration statement has been filed
with the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy be accepted in the United
States prior to the time the registration statement becomes effective. This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy, nor shall there be any sale of these securities in any State,
Province or other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of
any such State, Province or other jurisdiction.

Copies of the United States prospectus, when available, may be obtained by U.S.
residents from Citigroup Global Markets Inc. at Brooklyn Army Terminal, 140 58th
Street, Brooklyn, NY 11220, Attn: Prospectus Department, telephone: (718)
765-6732.

OccuLogix, Inc. is an ophthalmic therapeutic company founded in 1996 to
commercialize innovative treatments for eye diseases.



FOR FURTHER INFORMATION PLEASE CONTACT:
TLC Vision Corporation
Stephen Kilmer
(905) 238-3904